je.st
news
Tag: merck
The Dow Can't Hold New Highs as Merck, UnitedHealth Fall
2014-05-09 13:45:28| Beverages - Topix.net
Still, the Dow managed to do much better than the rest of the stock market, as both the S&P 500 and the Nasdaq lost ground on the day.
AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients
2014-05-08 15:00:00| Merck.com - Research & Development News
Dateline City: WUPPERTAL, Germany & WHITEHOUSE STATION, N.J. WUPPERTAL, Germany & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--AiCuris and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy of letermovir, an investigational, oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orInvestors:Carol Ferguson, 908-423-4465orAiCurisMedia:Katja Woestenhemke, +49-202-317-63-1176 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
publication
journal
agent
U.S. stock futures fall; Merck in focus
2014-05-06 19:41:22| Grocery - Topix.net
U.S. stock futures reversed gains Tuesday as investors digested a trade deficit that generally met expectations as well as earnings and deal news in the pharmaceutical sector.
Tags: stock
fall
focus
futures
Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&D Focus; Drive Growth and Productivity
2014-05-06 14:59:00| Merck.com - Corporate News
Dateline City: BOSTON Company Provides Updates on Near-Term Opportunities and Immuno-Oncology Strategy Announced Sale of Consumer Care Business to Bayer AG for $14.2 Billion; Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease MK-3475 BLA Accepted for Priority Review by FDA; Company Announced Plans to File in EU in 2014 Provided Updates on Clinical Development Programs for Oncology, Hepatitis C and HIV Confirmed Plans to File Odanacatib for the Treatment of Osteoporosis in Second Half of 2014 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today is hosting an Investor Briefing at the companys research facility in Boston. The briefing is also available via webcast at www.merck.com starting at 9:00 a.m. EDT. Language: English Contact: MerckMedia:Steve Cragle, 908-423-3461Ian McConnell 908-423-3046Investor:Joe Romanelli, 908-423-5185Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: drive
commercial
focus
growth
Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma
2014-05-06 14:40:00| Merck.com - Corporate News
Dateline City: BOSTON Priority Review Designation for MK-3475 BLA for Proposed Indication of Unresectable or Metastatic Melanoma in Patients Who Have Been Previously Treated with Ipilimumab Advancing New Phase 3 Studies with MK-3475 in Adjuvant Melanoma, Previously-Untreated Non-Small Cell Lung Cancer, Advanced Head & Neck and Bladder Cancers Data from Studies in Three Different Cancer Types to be presented at 2014 ASCO Annual Meeting Initiating Phase 1 Study with Investigational Anti-GITR Antibody (MK-4166) BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-3475, Mercks investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab. Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
Sites : [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] next »